Results 11 to 20 of about 57,759 (194)

Alternative temozolomide dosing regimens and novel combinations for the treatment of advanced metastatic melanoma

Oncology Reviews, 2011
Over the past 30 years, there has been no significant improvement in treatment outcomes for patients with advanced stage IV metastatic melanoma, and prognosis remains poor.
Wen-Jen Hwu, Ana E. Ayala, Ingrid M. Hernandez   +2 more
doaj   +1 more source

Mifepristone as a Potential Therapy to Reduce Angiogenesis and P-Glycoprotein Associated With Glioblastoma Resistance to Temozolomide

Frontiers in Oncology, 2020
Glioblastoma, the most common primary central nervous system tumor, is characterized by extensive vascular neoformation and an area of necrosis generated by rapid proliferation.
Monserrat Llaguno-Munive, Monserrat Llaguno-Munive, Sebastián León-Zetina, Inés Vazquez-Lopez, María del Pilar Ramos-Godinez, Luis A. Medina, Luis A. Medina, Patricia Garcia-Lopez   +7 more
doaj   +1 more source

Temozolomide in aggressive pituitary adenomas and carcinomas

Clinics, 2012
Temozolomide is an alkylating agent used in the treatment of gliomas and, more recently, aggressive pituitary adenomas and carcinomas. Temozolomide methylates DNA and, thereby, has antitumor effects.
Leon D. Ortiz, Luis V. Syro, Bernd W. Scheithauer, Fabio Rotondo, Humberto Uribe, Camilo E. Fadul, Eva Horvath, Kalman Kovacs   +7 more
doaj   +1 more source

Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma

ESMO Open, 2020
Background Most glioblastoma tumours exhibit intrinsic phosphatidylinositol 3-kinase (PI3K) pathway activation. Preclinical in vitro and in vivo models suggest that buparlisib (an oral pan-PI3K inhibitor) can have an effect on glioblastoma directly and ...
David Mills, Patrick Yung Wen, Jordi A Rodon, Warren Mason, Joseph T Beck, John DeGroot, Valerie Donnet, Mona El-Hashimy, Mark Rosenthal   +8 more
doaj   +1 more source

Bortezomib abrogates temozolomide-induced autophagic flux through an ATG5 dependent pathway

Frontiers in Cell and Developmental Biology, 2022
Introduction: Glioblastoma (GBM) is invariably resistant to temozolomide (TMZ) chemotherapy. Inhibiting the proteasomal pathway is an emerging strategy to accumulate damaged proteins and inhibit their lysosomal degradation.
Mohummad Aminur Rahman, Mohummad Aminur Rahman, Agnete S. T. Engelsen, Agnete S. T. Engelsen, Shahin Sarowar, Christian Bindesbøll, Even Birkeland, Dorota Goplen, Maria L. Lotsberg, Maria L. Lotsberg, Stian Knappskog, Stian Knappskog, Anne Simonsen, Anne Simonsen, Anne Simonsen, Martha Chekenya   +15 more
doaj   +1 more source

Combining Bevacizumab with Temozolomide Increases the Antitumor Efficacy of Temozolomide in a Human Glioblastoma Orthotopic Xenograft Model

Neoplasia: An International Journal for Oncology Research, 2008
Purpose: The aims of the present work were to investigate the in vitro and in vivo antiangiogenic effects of chronic temozolomide treatment on various glioma models and to demonstrate whether bevacizumab (Avastin) increased the therapeutic benefits ...
Véronique Mathieu, Nancy De Nève, Marie Le Mercier, Janique Dewelle, Jean-François Gaussin, Mischael Dehoux, Robert Kiss, Florence Lefranc   +7 more
doaj   +1 more source

An Unusual Case of Aplastic Anemia Caused by Temozolomide

Case Reports in Medicine, 2010
Radiotherapy and concomitant/adjuvant therapy with temozolomide are a common treatment regimen for children and adults with high-grade glioma. Although temozolomide is generally safe, it can rarely cause life-threatening complications.
Gazi Comez, Alper Sevinc, Ozlem Nuray Sever, Taner Babacan, Ibrahim Sarı, Celalettin Camci   +5 more
doaj   +1 more source

Acute lymphoblastic leukemia subsequent to temozolomide use in a 26-year-old man: a case report

Journal of Medical Case Reports, 2010
Introduction We report the development of acute lymphoblastic leukemia in a patient in whom temozolomide was used for the treatment of a brain tumor. Unlike that of other alkylating agents, the leukemogenic potential of temozolomide is considered to be ...
Shaikh Asim, Masood Nehal
doaj   +1 more source

A Case of IDH-Mutant Astrocytoma Harboring an IDH2 R172_H173delinsSN Variant. [PDF]

Neuropathology
ABSTRACT IDH‐mutant gliomas most commonly harbor the canonical IDH1 p.R132H mutation, followed by less common mutations involving IDH1 p.R132 or IDH2 p.R172 codons. We present a case of a 32‐year‐old male found to have a left temporal brain tumor with regional enhancement on brain MRI, for which he underwent resection.
Auen T, Chen J, Shonka N, Cathcart S.
europepmc   +2 more sources

Ex vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in vitro.

PLoS ONE, 2019
Glioblastoma is the leading malignant glioma with a poor prognosis. This study aimed to investigate the antitumor effects of natural killer cells in combination with temozolomide as the standard chemotherapeutic agent for glioblastoma.
Yoshitaka Tanaka, Tsutomu Nakazawa, Mitsutoshi Nakamura, Fumihiko Nishimura, Ryosuke Matsuda, Koji Omoto, Yoichi Shida, Toshiharu Murakami, Ichiro Nakagawa, Yasushi Motoyama, Hiromichi Morita, Takahiro Tsujimura, Hiroyuki Nakase   +12 more
doaj   +1 more source